7/16/2009 · Inflexal ® V is the only virosomal adjuvanted influenza vaccine licensed for all age groups. During its 11 years on the market, Inflexal ® V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and very low levels of.
Epaxal (hepatitis A vaccine) and Inflexal V (influenza vaccine) will be discontinued by Crucell, part of Janssen, during 2014. Vivotif (typhoid vaccine) will continue to be available until at least the end of April 2014, after which Vivotif will also be discontinued if “divestment” is not possible.
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal ® V . Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal ® V have been completed in which 3920 subjects participated.
Inflexal V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children.
For example, Inflexal V , a licensed virosome?based vaccine with a diameter of ?150 nm, has shown an excellent immunogenicity and tolerability profile in both healthy and immunocompromised people. However, this vaccine was discontinued in 2014 due to bacterial contamination during a complicated and multi?step manufacturing process.
Inflexal ® V is a virosomal-adjuvanted, inactivated influenza vaccine. The hemagglutinin is extracted from the influenza virus and is incorporated into the liposomal membranes. In one study, Inflexal ® V was shown to have a superior immune response compared to other vaccines, such as commercially available whole-virus and subunit vaccines …
The product name and trade name of vaccines licensed for use in the United States.
1/1/2020 · Berna Biotech and Crucell developed Inflexal V and Epaxal products for vaccinations against influenza and hepatitis, respectively. As discussed earlier, for the approval of liposome-based products, individuals can follow the 505(b) (2) pathway, as much of the time marketed liposome-based formulations contain therapeutic moieties which have been approved previously.
Influenza vaccines, also known as flu shots or flu jabs, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza.
Inflexal V este un vaccin gripal inactivat, formulat ca virozomi ca sistem purtator/adjuvant, compus din antigene de suprafata ale tulpinilor A si B ale virusului gripal, insamantate pe ou de gaina embrionat. Acest vaccin respecta recomandarile OMS (pentru emisfera nordica) si decizia Uniunii Europene pentru sezonul 2005/2006. Lista excipientilor
